Long term cost-effectiveness analysis of IDegLira in the treatment of type 2 diabetes patients compared to GLP-1RA added to basal insulin after IDegLira entered the national reimbursement drug list in China - Dunming Xiao; Junling Weng; Lei Zhang; Chang Xing; Yan Wei; Yingyao Chen (PLoS ONE, 2025)